Engeneos

Minerva Biotechnologies, based in Waltham, MA, is dedicated to advancing cancer and stem cell therapeutics, with a focus on developing immunotherapies that target nearly 80% of solid tumors. Their innovative CAR T therapeutics are designed to specifically attack MUC1 positive cancers, aiming to enhance treatment outcomes and address cancer metastasis. In addition to cancer therapeutics, Minerva is pioneering research in regenerative medicine through its discoveries related to stem cells, catering to various diseases. Their AlphaSTEM technology enables more efficient generation and differentiation of iPSCs, promising advancements in the field of regenerative therapies. Generated from the website